Clinical study of injectable Astragalus Polysaccharides as an adjuvant therapy for small cell lung cancer
Objective To analyze the clinical efficacy of injectable Astragalus Polysaccharides as an adjuvant therapy for small cell lung cancer(SCLC).Method According to different treatment methods,50 patients with SCLC were di-vided into control group and observation group,with 25 cases in each group.The patients in the control group received et-oposide+cisplatin(EP)regimen chemotherapy,while the patients in the observation group received EP regimen chemo-therapy combined with injectable Astragalus Polysaccharides.The clinical efficacy,immune function indicators(CD3+,CD4+,CD8+,CD4+/CD8+),hematologic indicators[white blood cell count,neuron specifiic enolase(NSE)and carcinoem-bryonic antigen(CEA)]and incidence of adverse reactions were compared between the two groups.Result The disease control rate(DCR)of the observation group was 88.00％,which was higher than 64.00％of the control group,and the dif-ference was statistically significant(P＜0.05).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+in the observa-tion group were higher than those before treatment and the control group,and the level of CD8+was lower than those be-fore treatment and the control group,and the differences were statistically significant(P＜0.05).After treatment,the levels of CEA,NSE,and white blood cell count in both groups were lower than those before treatment,the levels of CEA and NSE in the observation group were lower than those in the control group,and white blood cell count was higher than that in the control group,and the differences were statistically significant(P＜0.05).The total incidence of adverse reactions in the observation group was 16.00％,which was significantly lower than 60.00％in the control group,and the difference was statistically significant(P＜0.01).Conclusion Injectable Astragalus Polysaccharides as an adjuvant therapy for SCLC can improve the therapeutic effect and immune function,and do not increase adverse reactions.
small cell lung cancerinjectable Astragalus Polysaccharidesadjuvant therapyetoposidecisplatin
万方数据
维普
